Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

[1]  D. Sasseville,et al.  Environmental and Other Extrinsic Risk Factors Contributing to the Pathogenesis of Cutaneous T Cell Lymphoma (CTCL) , 2019, Front. Oncol..

[2]  E. Jaffe,et al.  The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. , 2019, Blood.

[3]  D. Buckley,et al.  British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018 , 2018, The British journal of dermatology.

[4]  L. Specht,et al.  Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  D. Blaise,et al.  Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years , 2018, Bone Marrow Transplantation.

[6]  M. Weichenthal,et al.  Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial , 2017, The Lancet.

[7]  C. Klemke,et al.  European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. , 2017, European journal of cancer.

[8]  J. Scarisbrick.  New drugs in cutaneous T-cell lymphomas , 2016, Current opinion in oncology.

[9]  Karl Claxton,et al.  Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. , 2016, Health economics.

[10]  M. Tetzlaff,et al.  Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Morris,et al.  Estimating the cost of caring for people with cancer at the end of life: A modelling study , 2015, Palliative medicine.

[12]  R. Advani,et al.  Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Acaster,et al.  Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma , 2015, Leukemia & lymphoma.

[14]  M. Weinstock,et al.  Changing incidence trends of cutaneous T-cell lymphoma. , 2013, JAMA dermatology.

[15]  S. Theurich,et al.  Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. , 2013, The Cochrane database of systematic reviews.

[16]  Wei Wei,et al.  Long-term Outcomes of 1,263 Patients with Mycosis Fungoides and Sézary Syndrome from 1982 to 2009 , 2012, Clinical Cancer Research.

[17]  M. Chren.  The Skindex instruments to measure the effects of skin disease on quality of life. , 2012, Dermatologic clinics.

[18]  R. Dummer,et al.  EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. , 2011, Blood.

[19]  J. Scarisbrick,et al.  Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Advani,et al.  Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. , 2009, Archives of dermatology.

[21]  S. Devesa,et al.  Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. , 2009, Blood.

[22]  S. Horwitz,et al.  Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[23]  Nicola Pimpinelli,et al.  Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). , 2007, Blood.

[24]  R. Dummer,et al.  EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. , 2006, European journal of cancer.

[25]  Nicola Pimpinelli,et al.  WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.

[26]  R. Hoppe,et al.  CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. , 2003, Journal of the American Academy of Dermatology.

[27]  S. Whittaker,et al.  Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T‐cell lymphomas , 2003, The British journal of dermatology.

[28]  E. Vellenga,et al.  Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. a prospective randomised trial. , 2001, European journal of cancer.

[29]  C. Meijer,et al.  Primary and secondary cutaneous CD30+lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment , 2000 .

[30]  A. B. Prasad,et al.  British National Formulary , 1994 .

[31]  S. Lade,et al.  Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. , 2015, Blood.

[32]  C. Meijer,et al.  Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. , 2000, Blood.